Table 4.

Core Gene Pathway Alterations and Association with Patients’ Survival in Resectable KRAS^mut PDAC

Mutated pathwayn and other factors	Number	Disease-free survival in KRASmut (n=458)			Overall survival in KRASmut (n=458)
		Median (mo)	HR (95% CI)	P	Median (mo)	HR [95% CI]	P
KRAS
G12D	220 (48.0%)	11.83 [9.65–14.01]	1 [Reference]	1	21.07 [18.49–23.65]	1 [Reference]	1
Other codon	238 (52.0%)	13.97 [11.93–16.01]	0.823 [0.663–1.020]	0.075	23.30 [21.79–24.81]	0.839 [0.665–1.059]	0.139
TP53
WT	164 (35.8%)	17.30 [14.88–19.72]	1 [Reference]	1	26.97 [20.98–32.96]	1 [Reference]	1
Mutated	294 (64.2%)	10.60 [9.14–12.06]	1.390 [1.102–1.752]	0.005	21.03 [18.54–23.52]	1.287 [1.003–1.651]	0.047
Cell cycle
WT	376 (82.1%)	13.90 [11.70–16.10]	1 [Reference]	1	23.30 [21.19–25.41]	1 [Reference]	1
Mutated	82 (17.9%)	10.60 [7.97–13.23]	1.388 [1.059–1.818]	0.017	19.23 [16.33–22.13]	1.385 [1.034–1.855]	0.029
TGFb
WT	365 (79.7%)	13.63 [11.54 – 15.72]	1 [Reference]	1	23.23 [21.19–25.27]	1 [Reference]	1
Mutated	93 (20.3%)	10.07 [7.01 - 13.13]	1.201 [0.929–1.552]	0.162	18.77 [14.42–23.12]	1.165 [0.883–1.537]	0.280
Trithorax
WT	362 (79.0%)	12.93 [10.96 - 14.90]	1 [Reference]	1	22.43 [20.54–24.32]	1 [Reference]	1
Mutated	96 (21.0%)	12.83 [9.76 - 15.90]	0.917 [0.705–1.193]	0.519	23.10 [20.18–26.02]	0.903 [0.656–1.243]	0.532
Male	273 (59.6%)		1.198 [0.966–1.485]	0.099		1.153 [0.912–1.458]	0.233
Age > 70y	108 (23.6%)		1.070 [0.814–1.407]	0.627		1.061 [0.785–1.435]	0.699
Vascular invasion	159 (34.7%)		1.209 [0.952–1.537]	0.120		1.243 [0.962–1.604]	0.096
Poor differentiated	228 (49.8%)		1.573 [1.270–1.949]	<0.001		1.645 [1.303–2.076]	<0.001
Tumor >3cm	170 (37.1%)		1.439 [1.139–1.816]	0.002		1.336 [1.046–1.706]	0.020
N1-2	240 (52.4%)		1.412 [1.140–1.749]	0.002		1.497 [1.189–1.885]	0.001
R1 margin status	72 (15.7%)		1.211 [0.902–1.625]	0.203		1.395 [1.024–1.899]	0.035
Chemotherapy	329 (71.8%)		0.571 [0.443–0.736]	<0.001		0.042 [0.304–0.531]	<0.001